Reviva Pharmaceuticals Inc.

Reviva Pharmaceuticals Reports Positive Top-Line Results from a Phase 2 Clinical Trial of RP5063 for the Treatment of Schizophrenia and Schizoaffective Disorder (April 9, 2013)

Reviva Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of RP5063 for the Treatment of Schizophrenia and Schizoaffective Disorder (January 14, 2013)

Reviva presented RP5063 Phase 1 clinical results at the NCDEU conference (May 29-June 1, 2012)

Reviva Pharmaceuticals Announces Enrollment of Patients in Phase 2 Clinical Study of RP5063 for the Treatment of Schizophrenia and Schizoaffective Disorder (March 12, 2012)

Reviva interview with MergerMarket - A Financial Times Publication (February 6, 2012)

Reviva News Release (September 2011)

IMS R&D Focus Drug News (November 2010)


5941 Optical Court, San Jose, CA 95138. Map this location Telephone:+1 408 960 2209 FAX:+1 408 904 6270 Web : www.revivapharma.com